Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.

Daniel K NomahJuliana Maria Reyes-UrueñaYesika DíazSergio MorenoJordi AceitonAndreu BrugueraRosa M Vivanco-HidalgoJordi CasabonaPere Domingo Jordi NavarroArkaitz ImazElisabet DeigGemma NavarroJosep Maria LlibreJose M Mironull null

Published in: The Journal of antimicrobial chemotherapy (2022)

TAF/FTC or TDF/FTC were not associated with reduced SARS-CoV-2 diagnosis rates or associated hospitalizations among PLWH. TDF/FTC users had baseline characteristics intrinsically associated with more benign SARS-CoV-2 infection outcomes. Tenofovir exposure should not modify any preventive or therapeutic SARS-CoV-2 infection management.

Keyphrases

respiratory syndrome coronavirus
sars cov
coronavirus disease
antiretroviral therapy
early onset
metabolic syndrome
skeletal muscle
insulin resistance